Stock prices of multiple cancer drug companies soared Monday following the release of positive clinical trial results for their therapies at an ongoing industry conference in Chicago.
(Reuters) - Shares of several cancer drug firms surged on Monday after the companies reported positive clinical trial data from their therapies at an .
Shares of several cancer drug firms surged on Monday after the companies reported positive clinical trial data from their therapies at an ongoing industry conference in Chicago.
Blueprint Medicines Co. (NASDAQ:BPMC – Get Rating) was the recipient of a large decline in short interest during the month of May. As of May 15th, there was short interest totalling 3,580,000 shares, a decline of 5.8% from the April 30th total of 3,800,000 shares. Based on an average trading volume of 598,200 shares, the […]
Blueprint Medicines (NASDAQ:BPMC – Get Rating) had its price target lifted by Barclays from $44.00 to $46.00 in a research report sent to investors on Tuesday, The Fly reports. A number of other analysts have also issued reports on the company. Stifel Nicolaus boosted their price objective on Blueprint Medicines from $80.00 to $84.00 in […]